Partnership to Understand Viral and Immune Factors in HIV-Related Cancers
Official title: Partnership to Assess Viral and Immune Landscape Intersections with ONcology for People Living with HIV (PAVILION)
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11418481 · Data updated 2026-11-12
A collaboration of HIV, virus-related cancer, and immune researchers will study virus-driven cancers that affect people living with HIV to improve prevention, detection, and treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | August 3, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $554,444 |
| NIH project number | 5U54CA277834-04 |
| Project ID | NIH-11418481 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults living with HIV who are at risk for or have experience with virus-associated cancers, including HPV- and EBV-related tumors.
✕Less likely to help
Some participants may not directly benefit during the study but could contribute to advancing knowledge that helps others.
What this research studies
This program brings together leading HIV and cancer researchers across sites to study understudied virus-associated tumors that disproportionately affect people living with HIV. It focuses on how viruses, immune responses, and clinical factors drive cancer risk and outcomes in PLWH, aiming to identify better prevention and treatment strategies. The project emphasizes collaboration, data sharing, and integrating virology, immunology, and oncology to address disparities in cancer care for HIV-positive individuals. The effort involves multiple experienced research sites and targets cancers linked to HIV, HPV, and EBV with poor understanding today.
Why it matters
Potential benefit: If successful, this work could lead to earlier cancer detection, tailored therapies, and improved survival for people living with HIV who are at risk for virus-associated cancers.
How similar studies have gone: Previous efforts highlight the importance of virus-immune interactions in HIV-associated cancers, but this program targets understudied tumors and stronger collaboration across institutions.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Giuliano, Anna R. — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Giuliano, Anna R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.